Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Specialized intestinal failure units have recently reported their outcomes with teduglutide to evaluate if they are consistent with the phase III trials results. SBS- intestinal failure patients are very heterogenous including their response to this treatment, hence the importance of real-life studies beyond the context of clinical trials. Moreover, it is essential to find a consensus on criteria identifying candidate patients for teduglutide. In addition, the impact of teduglutide on quality of life and its cost-effectiveness are emerging as well as new enterohormone treatments are being studied whether it is long action GLP-2 analog or other ileocolonic break hormones like glucagon-like peptide-1 analog. SUMMARY: Hormonotherapy is currently modifying the natural history of patients with SBS- intestinal failure by decreasing their need for parenteral support and possibly even complications associated with long-term parenteral support. Enterohormone treatment is now the cornerstone in SBS- intestinal failure and should be offered as a first-line therapy to selected patients.
|
Authors | Dane Christina Daoud, Francisca Joly |
Journal | Current opinion in clinical nutrition and metabolic care
(Curr Opin Clin Nutr Metab Care)
Vol. 23
Issue 5
Pg. 344-349
(09 2020)
ISSN: 1473-6519 [Electronic] England |
PMID | 32618723
(Publication Type: Journal Article, Review)
|
Chemical References |
- Gastrointestinal Agents
- Gastrointestinal Hormones
- Peptides
- teduglutide
|
Topics |
- Gastrointestinal Agents
(therapeutic use)
- Gastrointestinal Hormones
(therapeutic use)
- Humans
- Intestinal Diseases
(drug therapy, etiology)
- Intestines
(drug effects)
- Peptides
(therapeutic use)
- Short Bowel Syndrome
(complications)
|